Nurix Therapeutics Inc
NASDAQ:NRIX

Watchlist Manager
Nurix Therapeutics Inc Logo
Nurix Therapeutics Inc
NASDAQ:NRIX
Watchlist
Price: 22.05 USD -1.43% Market Closed
Market Cap: 1.6B USD
Have any thoughts about
Nurix Therapeutics Inc?
Write Note

Intrinsic Value

NRIX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one NRIX stock under the Base Case scenario is 10.54 USD. Compared to the current market price of 22.05 USD, Nurix Therapeutics Inc is Overvalued by 52%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NRIX Intrinsic Value
10.54 USD
Overvaluation 52%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Nurix Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for NRIX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about NRIX?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Nurix Therapeutics Inc

Provide an overview of the primary business activities
of Nurix Therapeutics Inc.

What unique competitive advantages
does Nurix Therapeutics Inc hold over its rivals?

What risks and challenges
does Nurix Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Nurix Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Nurix Therapeutics Inc.

Provide P/S
for Nurix Therapeutics Inc.

Provide P/E
for Nurix Therapeutics Inc.

Provide P/OCF
for Nurix Therapeutics Inc.

Provide P/FCFE
for Nurix Therapeutics Inc.

Provide P/B
for Nurix Therapeutics Inc.

Provide EV/S
for Nurix Therapeutics Inc.

Provide EV/GP
for Nurix Therapeutics Inc.

Provide EV/EBITDA
for Nurix Therapeutics Inc.

Provide EV/EBIT
for Nurix Therapeutics Inc.

Provide EV/OCF
for Nurix Therapeutics Inc.

Provide EV/FCFF
for Nurix Therapeutics Inc.

Provide EV/IC
for Nurix Therapeutics Inc.

Show me price targets
for Nurix Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Nurix Therapeutics Inc?

How accurate were the past Revenue estimates
for Nurix Therapeutics Inc?

What are the Net Income projections
for Nurix Therapeutics Inc?

How accurate were the past Net Income estimates
for Nurix Therapeutics Inc?

What are the EPS projections
for Nurix Therapeutics Inc?

How accurate were the past EPS estimates
for Nurix Therapeutics Inc?

What are the EBIT projections
for Nurix Therapeutics Inc?

How accurate were the past EBIT estimates
for Nurix Therapeutics Inc?

Compare the revenue forecasts
for Nurix Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Nurix Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Nurix Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Nurix Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Nurix Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Nurix Therapeutics Inc with its peers.

Analyze the financial leverage
of Nurix Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Nurix Therapeutics Inc.

Provide ROE
for Nurix Therapeutics Inc.

Provide ROA
for Nurix Therapeutics Inc.

Provide ROIC
for Nurix Therapeutics Inc.

Provide ROCE
for Nurix Therapeutics Inc.

Provide Gross Margin
for Nurix Therapeutics Inc.

Provide Operating Margin
for Nurix Therapeutics Inc.

Provide Net Margin
for Nurix Therapeutics Inc.

Provide FCF Margin
for Nurix Therapeutics Inc.

Show all solvency ratios
for Nurix Therapeutics Inc.

Provide D/E Ratio
for Nurix Therapeutics Inc.

Provide D/A Ratio
for Nurix Therapeutics Inc.

Provide Interest Coverage Ratio
for Nurix Therapeutics Inc.

Provide Altman Z-Score Ratio
for Nurix Therapeutics Inc.

Provide Quick Ratio
for Nurix Therapeutics Inc.

Provide Current Ratio
for Nurix Therapeutics Inc.

Provide Cash Ratio
for Nurix Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Nurix Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Nurix Therapeutics Inc?

What is the current Free Cash Flow
of Nurix Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Nurix Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Nurix Therapeutics Inc

Current Assets 456m
Cash & Short-Term Investments 448.1m
Other Current Assets 8m
Non-Current Assets 57.6m
Long-Term Investments 9.5m
PP&E 44.2m
Other Non-Current Assets 3.9m
Current Liabilities 86.3m
Accounts Payable 3.9m
Accrued Liabilities 34.4m
Other Current Liabilities 48m
Non-Current Liabilities 50.4m
Other Non-Current Liabilities 50.4m
Efficiency

Earnings Waterfall
Nurix Therapeutics Inc

Revenue
56.4m USD
Operating Expenses
-250.1m USD
Operating Income
-193.7m USD
Other Expenses
16.7m USD
Net Income
-177m USD

Free Cash Flow Analysis
Nurix Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

NRIX Profitability Score
Profitability Due Diligence

Nurix Therapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Negative Revenue Growth Forecast
Negative 1-Year Revenue Growth
Declining ROE
16/100
Profitability
Score

Nurix Therapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

NRIX Solvency Score
Solvency Due Diligence

Nurix Therapeutics Inc's solvency score is 77/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
High Altman Z-Score
Long-Term Solvency
77/100
Solvency
Score

Nurix Therapeutics Inc's solvency score is 77/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NRIX Price Targets Summary
Nurix Therapeutics Inc

Wall Street analysts forecast NRIX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NRIX is 31.82 USD with a low forecast of 16.16 USD and a high forecast of 43.05 USD.

Lowest
Price Target
16.16 USD
27% Downside
Average
Price Target
31.82 USD
44% Upside
Highest
Price Target
43.05 USD
95% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for NRIX?

Click here to dive deeper.

Dividends

Nurix Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for NRIX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

NRIX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Nurix Therapeutics Inc Logo
Nurix Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.5B USD

Dividend Yield

0%

Description

Nurix Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 242 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other challenging diseases. The company leverages its DELigase, an integrated discovery platform to identify and advance drug candidates targeting E3 ligases. Its drug candidate includes NX-2127, NX-5948, NX-1607, DeTIL-0255, KINASE-CTM3, COVID-CTMs, LIGASE-INH2 and DeCART. Its lead drug candidate, NX-2127, is an orally available Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies. Its lead drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. Its KINASE-CTM3, a kinase involved in T cell growth and activation to treat T cell malignancies and autoimmune disease.

Contact

CALIFORNIA
San Francisco
1700 Owens St Ste 205
+14156605320.0
www.nurixtx.com

IPO

2020-07-24

Employees

242

Officers

CEO, President & Director
Dr. Arthur T. Sands M.D., Ph.D.
Chief Financial Officer
Mr. Johannes Van Houte
Chief Scientific Officer
Dr. Gwenn M. Hansen Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Arthur Weiss M.D., Ph.D.
Senior Accounting Manager
Rita Kwong
Chief Technical Officer
Dr. Pasit Phiasivongsa Ph.D.
Show More
Chief Legal Officer, Secretary & Chief Compliance Officer
Dr. Christine Ring J.D., Ph.D.
Chief People Officer
Mr. Eric C. Schlezinger J.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one NRIX stock?

The intrinsic value of one NRIX stock under the Base Case scenario is 10.54 USD.

Is NRIX stock undervalued or overvalued?

Compared to the current market price of 22.05 USD, Nurix Therapeutics Inc is Overvalued by 52%.

Back to Top